Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12858877 | 1.00 | MAPK1 (0.50) | MAPK1MCHR1 | |
| SCHEMBL12408484 | 1.00 | MAPK1 (0.50) | MAPK1MCHR1 | |
| SCHEMBL9964658 | 0.89 | MAPK1 (0.55) | MAPK1MCHR1 | |
| SCHEMBL24587381 | 0.80 | MAPK1 (0.46) | MAPK1MCHR1 | |
| SCHEMBL27625701 | 0.80 | MAPK1 (0.37) | MAPK1 | |
| SCHEMBL18598783 | 0.78 | MAPK1 (0.30) | MAPK1 | |
| SCHEMBL2152830 | 0.76 | MAPK1 (0.52) | MAPK1MCHR1 | |
| SCHEMBL1476882 | 0.76 | MAPK1 (0.52) | MAPK1MCHR1 | |
| SCHEMBL12889635 | 0.76 | MAPK1 (0.52) | MAPK1MCHR1 | |
| SCHEMBL5951333 | 0.74 | MAPK1 (0.50) | MAPK1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8936781-B2 | Macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8936781-B2 | Macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20110033420-A1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110033420-A1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033420-A1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | CTSC, HAVCR2, DPP4 | MAPK1 2335/4885MCHR1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.